JWH-247

JWH-247 is a synthetic cannabinoid that acts as a potent agonist of the cannabinoid receptors. It was developed by John W. Huffman and his team at Clemson University as part of research into the structure-activity relationships of cannabinoids.

Chemical Structure and Properties

JWH-247 belongs to the naphthoylindole family of synthetic cannabinoids. Its chemical structure is characterized by a naphthalen-1-yl group attached to a methanone moiety, which is further linked to an indole core. The presence of a 1,1-dimethylheptyl side chain and two methoxy groups on the phenyl ring contribute to its high affinity for cannabinoid receptors.

Pharmacology

JWH-247 is a full agonist at both the CB1 and CB2 cannabinoid receptors, with a higher affinity for the CB1 receptor. This receptor is primarily found in the central nervous system and is responsible for the psychoactive effects of cannabinoids. The activation of CB1 receptors by JWH-247 leads to effects similar to those of tetrahydrocannabinol (THC), the active component of cannabis.

Legal Status

Due to its potential for abuse and lack of medical use, JWH-247, like many other synthetic cannabinoids, has been classified as a controlled substance in several countries. In the United States, it is listed as a Schedule I substance under the Controlled Substances Act.

Research and Applications

JWH-247 has been used in scientific research to study the effects of cannabinoid receptor activation. It has helped in understanding the role of these receptors in various physiological processes, including pain modulation, appetite regulation, and mood stabilization.

Health Effects and Risks

The use of JWH-247, particularly in recreational settings, poses significant health risks. Adverse effects can include tachycardia, hypertension, hallucinations, and psychosis. Long-term use may lead to dependence and withdrawal symptoms.

Also see

• Synthetic cannabinoids
• Cannabinoid receptor
• John W. Huffman
• CB1 receptor
• CB2 receptor